[Skip to Content]
[Skip to Content Landing]
Views 305
Citations 0
From The JAMA Network
August 4, 2016

Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer—What Now?

Author Affiliations
  • 1Knight Cancer Institute, Brenden-Colson Center for Pancreatic Care, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon
JAMA Oncol. Published online August 4, 2016. doi:10.1001/jamaoncol.2016.3012

At presentation, 30% of patients with pancreatic adenocarcinoma will have locally advanced unresectable disease. Optimal management of these patients has been unclear because no widely accepted international standard approach exists. Compared with patients with distant metastatic disease, patients with locally advanced unresectable disease have a slightly improved prognosis. Thus, it has been tempting to maximize local control with chemoradiotherapy. However, randomized clinical trials to date have failed to demonstrate a clear benefit in this patient subgroup for reasons including underpowered trials, poor accrual, lack of optimal systemic therapy or radiation therapy, and lack of radiation quality control. Moreover, a significant limitation of chemoradiation remains the disease biology itself—namely, the high prevalence of occult metastatic disease, rendering many patients unlikely to benefit from a local therapy approach.

First Page Preview View Large
First page PDF preview
First page PDF preview